Literature DB >> 22102435

Low-grade serous carcinomas of the ovary contain very few point mutations.

Siân Jones1, Tian-Li Wang, Robert J Kurman, Kentaro Nakayama, Victor E Velculescu, Bert Vogelstein, Kenneth W Kinzler, Nickolas Papadopoulos, Ie-Ming Shih.   

Abstract

It has been well established that ovarian low-grade and high-grade serous carcinomas are fundamentally different types of tumours. While the molecular genetic features of ovarian high-grade serous carcinomas are now well known, the pathogenesis of low-grade serous carcinomas, apart from the recognition of frequent somatic mutations involving KRAS and BRAF, is largely unknown. In order to comprehensively analyse somatic mutations in low-grade serous carcinomas, we applied exome sequencing to the DNA of eight samples of affinity-purified, low-grade, serous carcinomas. A remarkably small number of mutations were identified in seven of these tumours: a total of 70 somatic mutations in 64 genes. The eighth case displayed mixed serous and endometrioid features and a mutator phenotype with 783 somatic mutations, including a nonsense mutation in the mismatch repair gene, MSH2. We validated representative mutations in an additional nine low-grade serous carcinomas and 10 serous borderline tumours, the precursors of ovarian low-grade, serous carcinomas. Overall, the genes showing the most frequent mutations were BRAF and KRAS, occurring in 10 (38%) and 5 (19%) of 27 low-grade tumours, respectively. Except for a single case with a PIK3CA mutation, other mutations identified in the discovery set were not detected in the validation set of specimens. Our mutational analysis demonstrates that point mutations are much less common in low-grade serous tumours of the ovary than in other adult tumours, a finding with interesting scientific and clinical implications.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102435      PMCID: PMC3503448          DOI: 10.1002/path.3967

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  33 in total

1.  Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.

Authors:  Taymaa May; Carl Virtanen; Monika Sharma; Anca Milea; Heather Begley; Barry Rosen; K Joan Murphy; Theodore J Brown; Patricia A Shaw
Journal:  Gynecol Oncol       Date:  2010-02-01       Impact factor: 5.482

2.  Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.

Authors:  Bin Guan; Tsui-Lien Mao; Pradeep K Panuganti; Elisabetta Kuhn; Robert J Kurman; Daichi Maeda; Elizabeth Chen; Yung-Ming Jeng; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

4.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

Authors:  Hong Yang; Brian Higgins; Kenneth Kolinsky; Kathryn Packman; Zenaida Go; Raman Iyer; Stanley Kolis; Sylvia Zhao; Richard Lee; Joseph F Grippo; Kathleen Schostack; Mary Ellen Simcox; David Heimbrook; Gideon Bollag; Fei Su
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

5.  BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Authors:  Kwong-Kwok Wong; Yvonne T M Tsang; Michael T Deavers; Samuel C Mok; Zhifei Zu; Charlotte Sun; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson
Journal:  Am J Pathol       Date:  2010-08-27       Impact factor: 4.307

6.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

7.  ARID1A mutations in endometriosis-associated ovarian carcinomas.

Authors:  Kimberly C Wiegand; Sohrab P Shah; Osama M Al-Agha; Yongjun Zhao; Kane Tse; Thomas Zeng; Janine Senz; Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Alireza Heravi-Moussavi; Ryan Giuliany; Christine Chow; John Fee; Abdalnasser Zayed; Leah Prentice; Nataliya Melnyk; Gulisa Turashvili; Allen D Delaney; Jason Madore; Stephen Yip; Andrew W McPherson; Gavin Ha; Lynda Bell; Sian Fereday; Angela Tam; Laura Galletta; Patricia N Tonin; Diane Provencher; Dianne Miller; Steven J M Jones; Richard A Moore; Gregg B Morin; Arusha Oloumi; Niki Boyd; Samuel A Aparicio; Ie-Ming Shih; Anne-Marie Mes-Masson; David D Bowtell; Martin Hirst; Blake Gilks; Marco A Marra; David G Huntsman
Journal:  N Engl J Med       Date:  2010-09-08       Impact factor: 91.245

8.  Qualitative age interactions between low-grade and high-grade serous ovarian carcinomas.

Authors:  Philip M Grimley; Rayna K Matsuno; Philip S Rosenberg; Donald E Henson; Arnold M Schwartz; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-07-21       Impact factor: 4.254

9.  The genetic landscape of the childhood cancer medulloblastoma.

Authors:  D Williams Parsons; Meng Li; Xiaosong Zhang; Siân Jones; Rebecca J Leary; Jimmy Cheng-Ho Lin; Simina M Boca; Hannah Carter; Josue Samayoa; Chetan Bettegowda; Gary L Gallia; George I Jallo; Zev A Binder; Yuri Nikolsky; James Hartigan; Doug R Smith; Daniela S Gerhard; Daniel W Fults; Scott VandenBerg; Mitchel S Berger; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Carlos Clara; Peter C Phillips; Jane E Minturn; Jaclyn A Biegel; Alexander R Judkins; Adam C Resnick; Phillip B Storm; Tom Curran; Yiping He; B Ahmed Rasheed; Henry S Friedman; Stephen T Keir; Roger McLendon; Paul A Northcott; Michael D Taylor; Peter C Burger; Gregory J Riggins; Rachel Karchin; Giovanni Parmigiani; Darell D Bigner; Hai Yan; Nick Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2010-12-16       Impact factor: 47.728

10.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

Authors:  Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Jillian Temple; Andy G Lynch; Mohamed Riad; Raghwa Sharma; Colin Stewart; Sian Fereday; Carlos Caldas; Anna Defazio; David Bowtell; James D Brenton
Journal:  J Pathol       Date:  2010-05       Impact factor: 7.996

View more
  77 in total

1.  Whole exome sequence analysis of serous borderline tumors of the ovary.

Authors:  Jeff Boyd; Biao Luo; Suraj Peri; Beth Wirchansky; Lucinda Hughes; Caitlin Forsythe; Hong Wu
Journal:  Gynecol Oncol       Date:  2013-06-14       Impact factor: 5.482

2.  The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.

Authors:  Assaf Vestin; Alea A Mills
Journal:  Gene Expr Patterns       Date:  2013-10-09       Impact factor: 1.224

3.  Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2.

Authors:  Feng Rao; Jiyoung Cha; Jing Xu; Risheng Xu; M Scott Vandiver; Richa Tyagi; Robert Tokhunts; Michael A Koldobskiy; Chenglai Fu; Roxanne Barrow; Mingxuan Wu; Dorothea Fiedler; James C Barrow; Solomon H Snyder
Journal:  Mol Cell       Date:  2014-03-20       Impact factor: 17.970

4.  Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case.

Authors:  Mahkam Tavallaee; David F Steiner; James L Zehnder; Ann K Folkins; Amer K Karam
Journal:  Int J Gynecol Pathol       Date:  2019-07       Impact factor: 2.762

Review 5.  Low-grade Serous Tumors: Are We Making Progress?

Authors:  Nina Pauly; Sarah Ehmann; Enzo Ricciardi; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Sonia Prader; Stephanie Schneider; Andreas du Bois; Philipp Harter; Thaïs Baert
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

6.  Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Authors:  Marta Llauradó Fernández; Gabriel E DiMattia; Amy Dawson; Sylvia Bamford; Shawn Anderson; Bryan T Hennessy; Michael S Anglesio; Trevor G Shepherd; Clara Salamanca; Josh Hoenisch; Anna Tinker; David G Huntsman; Mark S Carey
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

7.  mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.

Authors:  Scott E Jordan; Heba Saad; Alex Sanchez Covarrubias; John Siemon; J Matt Pearson; Brian M Slomovitz; Marilyn Huang; Andre Pinto; Matthew Schlumbrecht; Sophia Hl George
Journal:  Gynecol Oncol       Date:  2020-09-18       Impact factor: 5.482

8.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

9.  Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Authors:  Rachel N Grisham; Brooke E Sylvester; Helen Won; Gregory McDermott; Deborah DeLair; Ricardo Ramirez; Zhan Yao; Ronglai Shen; Fanny Dao; Faina Bogomolniy; Vicky Makker; Evis Sala; Tara E Soumerai; David M Hyman; Nicholas D Socci; Agnes Viale; David M Gershenson; John Farley; Douglas A Levine; Neal Rosen; Michael F Berger; David R Spriggs; Carol A Aghajanian; David B Solit; Gopa Iyer
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

Review 10.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.